©2024 Stanford Medicine
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
Not Recruiting
Trial ID: NCT00185757
Purpose
The purpose of the study is to determine if the use of activated T cells can effectively
treat relapsed disease following allogeneic hematopoietic cell transplantation without
causing GVHD.
Official Title
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
Stanford Investigator(s)
Robert Negrin
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Eligibility
Inclusion Criteria:- Evidence of recurrent or persistent hematologic malignancy following
HLA matched allogeneic hematopoietic cell transplant
- eligible for DLI
- no evidence of GVHD
- stable immunosuppressive regimen
- adequate renal and liver function Exclusion Criteria:- CML patients who have not
received DLI, active infections
Intervention(s):
drug: Cytokine Induced Killer Cells
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822